Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aquestive Therapeutics's quarterly market cap
declined
from Dec. 2025 ($788.40 Mil) to Mar. 2026 ($515.78 Mil) but then
increased
from Mar. 2026 ($515.78 Mil) to Jun. 2026 ($522.13 Mil).
Aquestive Therapeutics's annual market cap
increased
from Dec. 2023 ($138.44 Mil) to Dec. 2024 ($325.43 Mil) and
increased
from Dec. 2024 ($325.43 Mil) to Dec. 2025 ($788.40 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aquestive Therapeutics's Enterprise Value for Today is $606.92 Mil.
Aquestive Therapeutics (NAS:AQST) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aquestive Therapeutics Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Aquestive Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Aquestive Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aquestive Therapeutics (AQST) has a Market Cap of $646.38 Mil as of Sep. 09, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aquestive Therapeutics and its competitors. According to the industry distribution chart, Aquestive Therapeutics ranks #348 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 34%.
Is Aquestive Therapeutics' Market Cap too high?
Aquestive Therapeutics' current Market Cap is $646.38 Mil. The Drug Manufacturers industry median Market Cap is 237.58. Aquestive Therapeutics' value of $646.38 Mil is 172.1% above this industry median. Based on the distribution chart, Aquestive Therapeutics ranks #348 out of 1023 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aquestive Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aquestive Therapeutics' Market Cap compare to TLRY and EOLS?
According to the Drug Manufacturers industry distribution chart, Aquestive Therapeutics ranks #348 out of 1023 companies for Market Cap. This puts Aquestive Therapeutics in the upper half of its industry. The industry median Market Cap is 237.58. Aquestive Therapeutics' value of $646.38 Mil is 172.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 237.58, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aquestive Therapeutics's current Market Cap of $646.38 Mil is 172.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aquestive Therapeutics and its competitors. For the Drug Manufacturers industry, the median Market Cap is 237.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aquestive Therapeutics's current Market Cap is $646.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aquestive Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aquestive Therapeutics (AQST) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.37, compared to a current price of $5.16 — trading 117.7% above its estimated fair value. The current Market Cap is $646.38 Mil and 172.1% above the Drug Manufacturers industry median of 237.58. Aquestive Therapeutics' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Aquestive Therapeutics (AQST), the current Market Cap is $646.38 Mil as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aquestive Therapeutics (AQST) Overvalued in 2026?
Based on GuruFocus' analysis, Aquestive Therapeutics stock appears to be overvalued.
The current stock price of $5.16 is trading 117.7% above its estimated GF Value™ of $2.37.
GuruFocus considers Aquestive Therapeutics to be Significantly Overvalued.
Key valuation signals for AQST:
Market Cap: $646.38 Mil
GF Value™: $2.37 vs. price of $5.16 (117.7% above fair value)
Industry Position: 172.1% above the Drug Manufacturers median (#348 of 1023)
No single metric tells the full story. See the AQST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
49GF Score
Get the complete analysis for AQST
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQST has been successfully added to your 
